Kraig Biocraft Laboratories Secures High‑Profile Spider Silk Order

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a U.S. company specializing in recombinant DNA technology for high‑strength, protein‑based fibers, announced on November 17, 2025 that it has received a substantial order for spider silk yarns from a leading performance‑sports apparel brand. The order is part of a confidential pilot development program aimed at producing next‑generation spider silk for elite‑tier athletic applications.

Order Details

  • Customer: A globally recognized performance sports apparel brand (name not disclosed).
  • Product: Recombinant spider silk yarns produced on Kraig Labs’ BAM‑1 Alpha platform.
  • Project Scope: Pilot development program focused on high‑performance athletic apparel.
  • Timeline: The program is designed for the most demanding and innovation‑focused segment of the athletic market.

Kraig Labs confirmed that the order will enable the company to deliver spider silk yarns for advanced athletic applications, further establishing its position as a world leader in spider silk technology.

Production Milestones

  • The company’s production program is entering a critical phase, with initial deliveries scheduled to begin shortly.
  • The BAM‑1 Alpha recombinant silk platform—Kraig Labs’ latest evolution—combines enhanced hybrid vigor and increased throughput to facilitate continuous, scalable output.
  • The platform is expected to provide the first large‑scale deployment of recombinant spider silk, positioning the company to showcase samples to potential clients in luxury, defense, and biomedical sectors.

Market Impact

  • The order underscores Kraig Labs’ ability to secure contracts with high‑profile brands in the competitive sports apparel market.
  • Successful delivery of the spider silk yarns will demonstrate the commercial viability of the BAM‑1 Alpha platform and could accelerate broader adoption of recombinant spider silk across multiple industries.

Kraig Biocraft Laboratories’ market capitalization stands at approximately $90.6 million USD. The company’s share price closed at $0.09 on November 16, 2025, with a 52‑week high of $0.14 and a low of $0.07. The firm’s price‑earnings ratio is negative, reflecting its investment focus on research and development rather than immediate profitability.

This development highlights Kraig Biocraft Laboratories’ continued progress in bringing innovative, sustainable, high‑performance materials to market, leveraging recombinant DNA technology to produce spider silk fibers that meet the demanding standards of elite athletic apparel manufacturers.